Ticker: SRRK | Industry: Biotechnology | CIK: 0001727196
Log in to follow this company
| Metric | Value |
|---|---|
| Core | |
| Market Cap | $4.5B |
| Enterprise Value | $4.3B |
| Total Cash | $369.6M |
| Total Revenue | N/A |
| Performance | |
| 1M Return | -2.2% |
| 3M Return | +55.0% |
| 6M Return | +13.1% |
| 1Y Return | -1.5% |
| Cash & Runway | |
| Cash Balance | $295.0K |
| Quarterly Cash Burn | $-68.9M |
| Runway (quarters) | 0.0 |
| Profitability (from burn) | No |
| Runway Commentary | runway into Q4 2026 |
| Metadata | |
| Last Updated | Jan 20, 2026 |
No clinical trials available for this company.
| Drug Name | Modality | Target | Disease | Therapeutic Area | Catalyst Details |
|---|---|---|---|---|---|
| apitegromab | Monoclonal Antibodies | myostatin | spinal muscular atrophy (SMA) | Orphan Disease - Muscular Dystrophy |
Resubmission of BLA and U.S. launch following approval (2026)
source
Commercial capacity reserved beginning in Q1 2026 (Q1 2026)
source
European Medicines Agency (EMA) regulatory review decision (mid-2026)
source
Initiated dosing in Phase 2 OPAL clinical trial (Ongoing)
source
|
| apitegromab | Monoclonal Antibodies | myostatin | neuromuscular disorder | Orphan Disease - General |
Initiate clinical development activities in a second neuromuscular disorder (End of 2025)
source
Provide additional information on the disease and the clinical development strategy (early 2026)
source
|
| SRK-439 | Monoclonal Antibodies | myostatin | N/A | Other |
Initiate dosing of SRK-439 in healthy volunteers (Q4 2025)
source
|
Investor Relations Page: https://investors.scholarrock.com/
Presentation Update Page: https://investors.scholarrock.com/investors-media/events-presentations